PCN24 - Duration of Treatment and Economic Burden in Patients with Anaplastic Lymphoma Kinase Positive (ALK+) Non–Small Cell Lung Cancer (NSCLC) Receiving Second-Line Alk Inhibitors.
Saved in:
| Title: | PCN24 - Duration of Treatment and Economic Burden in Patients with Anaplastic Lymphoma Kinase Positive (ALK+) Non–Small Cell Lung Cancer (NSCLC) Receiving Second-Line Alk Inhibitors. |
|---|---|
| Authors: | Lin, HM1, Hou, P1, Huang, H1, Desai, A1, Jahanzeb, M2 |
| Source: | Value in Health. 2018 Supplement 1, Vol. 21, pS17-S17. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
